In an amendment to an SEC filing, Medtronic’s
(NYSE: MDT)
Diabetes unit, MiniMed, today priced its planned initial public offering (IPO).
Medtronic announced in May that it planned to separate the Diabetes unit into a standalone, publicly traded company. In that announcement, the company projected the separation within the next 18 months.
It expects to complete the separation from Medtronic through a series of capital markets transactions. The company has the preferred path of an IPO and subsequent split-off. MiniMed plans to list its common stock on the Nasdaq market under the “MMED” ticker.
The company today filed an amendment to its SEC Form S-1, which it initially filed in late 2025. Its amendment includes the pricing of the IPO, which could reach up to $784 million. MiniMed is offering 28 million shares of common stock, priced between $25 and $28 apiece. If purchased at the $28 price point, the total proceeds of the IPO would reach that $784 million mark.
Get the full story at our sister site, Drug Delivery Business News.
